NCT01747083View on ClinicalTrials.gov

Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions

Type 2 Diabetes

Interventions

DRUG

FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY

NCT01747083 - Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets) | Biotech Hunter | Biotech Hunter